Although this discovery has provided the opportunity to develop anti-cancer therapies that selectively aim specific targets and greatly improve the survival of breast cancer patients, particularly the ones bearing ER+ tumors, the same therapies have met limited success in patients with HER2+ and TNBC tumors. Here, ESR1 is linked to breast carcinoma.